肝癌切除术时机的选择对原发性肝癌自发性破裂出血患者术后复发、腹腔转移及预后的影响

目的 探讨肝癌切除术时机的选择对原发性肝癌自发性破裂出血患者术后复发、腹腔转移及预后的影响.方法 回顾性分析68例原发性肝癌自发性破裂出血患者的病历资料.根据肝癌切除手术时机的选择不同将患者分为急诊手术组(n=28)和二期手术组(n=40).比较两组患者的围手术期指标,术后肝癌复发或腹腔转移情况及预后情况;并对可能影响患者术后复发或腹腔转移的因素进行分析.结果 急诊手术组的术中出血量、术中输血量均明显高于二期手术组,而总住院时间明显短于二期手术组,差异均有统计学意义(P﹤0.01);两组患者的手术时间比较,差异无统计学意义(P﹥0.05).两组患者的总生存率比较,差异无统计学意义(P﹥0.05);但急诊手术组患者的1年生存率明显高于二期手术组(78.5％vs 40.0％),差异有统计学意义(P﹤0.01).两组患者的术后复发率、腹腔转移率比较,差异均无统计学意义(P﹥0.05).COX回归分析结果显示,AFP水平(RR=2.05)、肿瘤直径(RR=2.46)是影响原发性肝癌自发性破裂出血患者术后复发或腹腔转移的独立危险因素(P﹤0.05).结论 行急诊手术治疗患者的短期预后优于行二期手术治疗的患者,二期肝切除手术治疗不会增加患者的术后复发率及腹腔转移率.AFP水平和肿瘤直径是原发性肝癌自发性破裂出血患者术后复发或腹腔转移的独立危险因素.     

原发性食管小细胞癌47例预后分析

目的:探讨局限期原发性食管小细胞癌的治疗和预后.方法:回顾性分析1989年5月-2006年3月期间在本院接受手术治疗的47例原发性食管小细胞癌的临床资料.结果:47例患者均接受了手术治疗,其中部分患者还接受了术后化疗和(或)放疗,全组患者的中位生存时间为10.3个月,1、3、5年的生存率分别为42.2%、12.1%和4.6%.单纯手术组的中位生存时间为8.2个月,术后化疗组和术后联合放、化疗组的预后要优于单纯手术组(P=0.000和P=0.038),单纯手术组与术后放疗组的生存比较差异无统计学意义(P=0.081).多因素分析显示临床分期是影响患者预后的主要因素(P=0.003).结论:手术联合放、化疗或化疗是治疗局限期原发性食管小细胞癌的主要手段,有助于延长患者的生存期.     

超声引导下经皮射频消融与腹腔镜手术治疗原发性肝癌的疗效及安全性比较

目的 比较超声引导下经皮射频消融与腹腔镜手术治疗原发性肝癌的疗效及安全性.方法 根据治疗方式将80例原发性肝癌患者分为消融组(n=42)和腹腔镜组(n=38),其中消融组患者接受超声引导下经皮射频消融治疗,腹腔镜组患者接受腹腔镜肝切除术治疗.比较两组患者的一般手术指标、肝功能指标、根治及复发情况、并发症发生情况及术后3...     

射频消融及125I粒子植入在预防肝癌切除术后局部复发的作用

目的探讨降低原发性肝癌切除术后局部复发的方法,提高肝癌患者的长期生存率。方法78例肿瘤靠近第一、第二肝门,估计切缘距肿瘤<1cm的肝癌患者,按就诊单双日分为单纯切除组和联合组。单纯切除组38例,仅行常规肝癌切除;联合组40例,在肝癌切除后,切缘行射频消融和~(125)I粒子植入。全部患者术后均定期随访。结果联合组术后1、3、5年肿瘤复发率分别为7.5%、30.0%和45.0%,术后1、3、5年生存率分别为92.5%、67.5%和30.0%,与单纯切除组比较,其中3、5年复发率差异有统计学意义((x~2=7.340,P<0.01;x~2=15.740,P<0.01);联合组的3、5年生存率较单纯切除组呈现明显升高的趋势。结论肝癌切除后切缘射频消融和~(125)I粒子植入能有效地降低术后局部复发率,提高治疗效果,且有可能延长肝癌患者的生存期。     

胰腺癌根治术与术后辅助外放疗的疗效比较

目的 探讨术后放疗对胰腺癌患者生存率的影响.方法 44例胰腺癌患者分为手术组(根治性外科切除)和手术+放疗组(根治性外科切除后接受外放疗),比较两组患者的治疗效果.结果 手术组平均生存期为453 d,中位生存期为379 d.手术+放疗组平均生存期789 d,中位生存期为665 d.手术组和手术+放疗组的1、3、5年生存率分别为46.3%、8.3%、4.2%和65.2%、20.2%、14.1%,手术+放疗组优于手术组(P=0.017).手术+放疗组局部复发率及区域淋巴结转移率低于手术组(P<0.05),且并发症发生率并不高于手术组(P>0.05).结论 胰腺癌根治术后结合放疗有助于改善患者生存期.     

原发性中小肝癌手术与射频消融治疗的疗效分析

目的:比较射频消融(radiofrequency ablation,RFA)治疗与手术切除治疗(surgical resection,SR)对于原发性小肝癌的疗效。方法:2003年1月到2009年6月共收治经甲胎蛋白(AFP)联合影像学(MRI或CT)证实的原发性中小肝癌患者125例:RFA组60例(B超引导下经皮射频消融51例,腹腔镜下射频消融6例,CT定位经皮射频消融3例),SR组65例:采用常规手术切除治疗(肿瘤局部挖出48例,肝段切除12例,肝叶切除5例)。评估并比较两组治疗效果。结果:RFA组和SR组术后第1、2和3年生存率分别为88.33%、71.67%、58.33%和93.85%、80.00%和72.31%,两者的生存曲线采用Kaplan-Meier检验有统计学意义(P=0.043)。RFA组和SR组术后第1、2和3年的肿瘤复发率分别为15.00%、31.67%、56.67%和10.77%、24.62%和36.92%,两组比较,复发率差异有统计学意义(P=0.034)。结论:射频消融治疗虽具有术后恢复快、出血量少、住院日短、花费少等微创特点,但在肿瘤复发率和术后生存率方面不如传统手术切除治疗。     

同时性结直肠癌肝转移患者治疗策略探讨

背景与目的:肝切除术是治疗同时性结直肠癌肝转移获得长期生存的希望.但如何选择肝切除术的手术时机,存在较大的争议,本研究探讨同时性结直肠癌肝转移的手术治疗策略.方法:选择上海东方肝胆外科医院和上海长海医院1995年1月至2005年12月收治的经手术治疗的83例同时性结直肠癌肝转移患者,其中37例行一期手术,46例行分期手术,比较两组手术并发症、死亡率、术中失血量、住院时间、生存率、中位生存期、无瘤生存期及肝转移癌复发率.结果:一期手术组手术并发症发生率为24.3%,分期手术组为19.6%(P=0.601).两组均没有手术死亡.一期手术组术中平均失血量为462 mL,分期手术组为574mL(P=0-312).一期手术组平均住院时间为19 d,分期手术组为36 d(P=0.001).一期手术组l、3、5年生存率分别为86.5%、54.1%和27.0%,分期手术组分别为89.1%(P-0.713)、52.2%(P=0.865)和23.9%(P=0.746).一期手术组中位生存期为40个月,分期手术组为37个月(丹0.075).一期手术组中位无瘤生存期为12个月,分期手术组为11个月(P=0.532).一期手术组肝转移癌复发率为35.1%,分期手术组为30.4% (P=0.650).结论:同时性结直肠癌肝转移患者有选择的一期手术切除原发病灶及肝转移病灶是合理的.     

原发性肝癌患者手术治疗远期疗效的影响因素

目的探讨原发性肝癌患者手术治疗远期疗效的影响因素.方法413例原发性肝癌并行肝部分切除术患者,剔除失访的41例后,对其余372例患者的远期生存状况进行观察,并对其相关影响因素进行分析.结果5年生存率为14.78%（55/372）,余317例死亡患者,根据术后是否存在复发转移分为复发转移组（n=194）与非复发转移组（n=123）.两组患者在有无乙肝及肝硬化、肿瘤大小、包膜完整与否、分化程度、是否存在血管癌栓及多结节融合等方面相对比,差异均有统计学意义（P〈0.05）;两组患者在术中出血量、输血情况、手术时间及肝门阻断时间、手术切缘、是否存在血管侵犯及肿瘤破裂等方面比较,差异并无统计学意义（P〉0.05）.经Logistic回归分析发现,乙肝、肝硬化、肿瘤大小、包膜完整与否、分化程度、多结节融合及血管癌栓是否存在,为影响原发性肝癌患者术后复发转移的独立危险因素（P〈0.05）.结论复发转移是影响患者远期生存状况的重要因素,而乙肝、肝硬化、肿瘤大小、包膜完整与否、分化程度、多结节融合及血管癌栓是否存在,为影响原发性肝癌患者术后复发转移的独立危险因素.     

手术切除347例原发性肝癌的临床分析

目的:探讨347例原发性肝癌手术切除的临床疗效及其影响因素.方法:对347例手术切除的原发性肝癌患者的临床资料和随访结果进行分析.结果:原发性肝癌手术切除的并发症发生率为6.34%(22/347),围手术期死亡率为1.15%(4/347).术后1、3和5年总生存率分别为87.96%、48.47%和22.82%.肿瘤直径＜3 cm的患者,其术后1、3和5年生存率分别为95.24%、83.33%和75.00%.肿瘤大小与术后1年生存率无明显相关性(P＞0.05),但肿瘤直径＞5 cm患者的术后3和5年生存率分别为41.88%和17.05%,明显低于肿瘤直径≤5 cm患者的77.78%和60.00%(P=0.000).结论:合理掌握原发性肝癌切除适应证以及根据肿瘤大小确定切缘距离能够降低并发症和围手术期死亡率,并提高生存率.定期监测原发性肝癌高危人群能够提高小肝癌的检出率.此外,术中B超能够有效定位小肝癌,甲胎蛋白是原发性肝癌完整切除和复发转移的敏感指标.     

原发性肝癌根治术后不同复发时期高危因素及疗效研究

目的探讨原发性肝癌根治切除术后近、远期复发的相关因素及治疗和预后。方法回顾性分析110例根治性切除并经病理证实的原发性肝细胞癌,总结其临床资料及病理学特征并行统计学分析。结果 （1）本组病例术后复发58例（复发率52.7%）,其中近期复发（≤12月）27例,远期（〉12月）31例。多因素COX回归分析门静脉分支癌栓为近期复发唯一危险相关因素（P=0.011）;肝组织HBVDNA含量、肿瘤手术切缘为远期复发危险因素（P〈0.05）。（2）近期复发多为肝内多发病灶（〉2个）（62.9%）,远期复发以单发灶为主（64.5%）,两组差异有统计学意义（P〈0.05）。（3）近、远期复发组术后3、5年生存率分别为37.1%、15.4%和76.5%、33.2%,两组差异有统计学意义（P〈0.01）。（4）复发病例治疗包括再手术、介入治疗（TACE、PEI、微波）,手术组生存率显著大于非手术组（P〈0.05）。结论肝癌术后近、远期复发相关危险因素不同,根据高危因素选择适当的治疗对于延长复发时间及生存期有重要意义。远期复发多为单发病灶,争取再手术切除仍可取得较好的疗效。     

老年肝癌患者的射频消融治疗

目的 比较射频消融治疗老年和非老年肝癌患者的临床疗效。方法回顾性分析比较2004年3月~2007年8月77例老年和非老年肝癌患者射频消融的治疗效果,年龄≥60岁者为老年组(n=31),＜60岁者为非老年组(n=46)。结果 老年组与非老年组比较,肿瘤完全清除率87.1％vs 82.6%(P=0.832),1~3年复发率分别为44.4％、59.8％、71.3％vs 56.4％、70.7％、78.1％(P=0.464)。1~3年生存率分别为89.6％、63.8％、35.9％vs 78.9％、46.6％、20.1％(P=0.114)。并发症的发生比率分别为29.0％vs 26.1％(P=0.776)。肿瘤个数、初治时是否复发及治疗后是否再复发是影响预后的危险因素,而年龄、肿瘤直径不是预后的影响因素。结论 对于老年肝癌患者PRFA治疗可以获得与非老年患者相当的长期生存率,而其微创、重复性好的优势更适合老年肝癌患者,尤其是复发癌患者。     

Clinical significance of preoperative platelet-to-lymphocyte ratio in recurrent hepatocellular carcinoma after thermal ablation: A retrospective analysis

Abstract

Purpose: The aim of this study was to elucidate the clinical significance of preoperative Platelet-to-lymphocyte ratio (PLR) in recurrent hepatocellular carcinoma (RHCC) patients after thermal ablation.

Materials and methods: We retrospectively reviewed 414 patients with RHCC treated with ultrasound-guided thermal ablation percutaneously between January 2010 and March 2014. The correlation of recurrence-free survival (RFS) with 15 clinical parameters was analysed by Cox multivariate proportional hazard model analysis. The best cut-off value of preoperative PLR was determined with time-dependent receiver operating characteristic (ROC) curve analysis. The value of PLR in predicting recurrence was analysed by Kaplan-Meier.

Results: Multivariate Cox proportional hazard model analysis showed that tumour differentiation, prothrombin time (PT), absolute lymphocyte count (ALC) and PLR were risk factors for recurrence in RHCC patients. PLR?≥?87.87 was considered for evaluation (AUROC?=?0.667; P?<?0.05), and 166 of 414 patients (40.1%) had PLR of more than 87.87. During the follow-up period (12–52 months), the 1- and 3-year recurrence rates were 39.9% and 54.8% in the low PLR group, which were significantly better than those in the high PLR group (56.0% and 79.5%) (P?<?0.05). Kaplan-Meier analysis demonstrated that the RFS in the low PLR group was 45.2% which was significantly higher than that of the high PLR group (20.5%) (X2?=?24.019, P?<?0.05). This result suggested that preoperative PLR is a predictor for recurrence followed thermal ablation in RHCC patients, and patients with PLR?≥?87.87 indicated higher RFS, which may improve the clinical management of RHCC patients. Further studies are warranted to validated this finding and test its clinical applicability in RHCC.     

多功能喉罩与气管插管在日间手术小细胞肝癌经皮射频消融术中的应用比较

背景与目的：经皮射频消融术(percutaneous radiofrequency ablation，PRFA)治疗小细胞肝癌(small hepatocellular carcinoma，HCC)效果得到认可并在日间手术室得到广泛开展。随着加速康复外科(enhanced recovery after surgery，ERAS)概念的兴起，选择合适的麻醉方法变得日益重要。比较多功能喉罩(multi-function intubating laryngeal mask，multi-function ILM)与气管插管在日间手术PRFA中的麻醉安全性。方法：择期全麻下经皮肝脏射频消融术患者140例，随机分为多功能喉罩组(A组)和气管插管组(B组)，记录并比较两组患者在麻醉诱导前(T₀)、插入喉罩/气管导管前(T₁)、插入喉罩/气管导管即刻(T₂)、插入后5 min(T₃)、10 min(T₄)、15 min(T₅)、拔出喉罩及气管导管即刻(T₆)的收缩压(systoLnc blood pressure，SBP)、舒张压(diastoLnc blood pressure，DBP)及心率(heart rate，HR)，同时记录平均气道压(P_mean)、气道峰压(P_peak)和P_ETCO₂，并观察呛咳、反流误吸、躁动、气道分泌物、拔管后低氧血症及咽喉疼痛等并发症，记录苏醒时间及患者术后满意度。结果：A组插入喉罩及气管导管即刻(T₂)的SBP、DBP及HR显著低于B组，波动更小，差异有统计学意义(P<0.05)；两组的苏醒时间差异有统计学意义(P<0.05)，A组苏醒更快；A组患者气道分泌物增多、喉咙疼痛等并发症明显少于B组，差异有统计学意义(P<0.05)，两组各时点通气效果、术中不良反应发生率及经济效益差异无统计学意义(P<0.05)。结论：多功能喉罩在行PRFA日间手术麻醉中通气效果良好，术后并发症少，安全可靠。对患者血流动力学影响较小，血压波动较小。苏醒期时间更短，有提高患者满意度、降低患者治疗时间的可能，在日间手术中有一定的优势。     

瑞芬太尼复合异丙酚静脉麻醉在肝癌射频消融术中的应用

背景与目的:经皮射频消融是治疗小肝癌的最新有效的微创手术,但手术的麻醉尚未得到重视,一般的局部麻醉或者单次使用镇痛药物均无法获得满意的效果.本研究将瑞芬太尼复合异丙酚应用于经皮射频消融治疗肝癌的麻醉,探讨其临床效果以及安全性.方法:选择射频治疗肝癌患者60例,随机分为瑞芬太尼复合异丙酚(R组)组与芬太尼复合异丙酚(F组)组,每组各30例.R组用微量泵输注瑞芬太尼0.1μg·kg-1·min-1,F组单次静注芬太尼1.5μg·kg-1,两组均以异丙酚微量泵维持麻醉.使用UT 4000型床边监护仪记录术前、手术开始时、手术开始后5 min及患者术后苏醒时的平均动脉压、心率、脉搏氧饱和度及呼吸频率,监测动脉血二氧化碳分压;记录患者苏醒时间;记录术中体动、呼吸暂停、胸肌强直次数.结果:R组患者的清醒时间[(5.0±1.8)min]显著短于F组[(10.7±3.0)min](P＜0.001).异丙酚用量R组[(172.0±37.3)mg]显著少于F组[(330.3±61.2)mg](P＜0.001).术中R组的平均动脉压下降明显低于F组(P＜0.05).术中体动R组(5例)少于F组(12例),呼吸暂停R组(12例)多于F组(6例).两组均未见胸肌强直.结论:肝癌射频消融术中应用微量泵静脉输注瑞芬太尼复合异丙酚麻醉效果确切、安全,但需要加强呼吸循环监护与管理.     

Risk factors of survival after percutaneous radiofrequency ablation of hepatocellular carcinoma

AIMS: This study aimed to determine the risk factors of survival in patients with hepatocellular carcinoma (HCC) undergoing percutaneous radiofrequency ablation (PRFA). PATIENTS AND METHODS: Between August 1999 and May 2005, 281 patients (250 males and 31 females) who were 33-80 years old (mean 65.3 years) received PRFA only or PRFA in combination with percutaneous ethanol injection (PEI) in our center. Patients were treated with PRFA or PEI by a percutaneous approach with ultrasound (US) guidance and were evaluated at regular intervals to determine disease recurrence and survival. The survival curves were constructed by the Kaplan-Meier method and compared by the log-rank test. The relative significance of the variables in the risk factors of overall survival was assessed by multivariate Cox proportional hazards regression analysis. RESULTS: At the end of the study, 189 patients were alive, and 92 were dead. Median survival was 48.7 months. The overall 1-, 3-, and 5-year survival rates were 89%, 54%, and 43%, respectively. The overall 1-, 3-, and 5-year survival rates for small tumor (size < or = 3cm) were 97.8%, 65.7%, 58.6%, respectively, for medium tumor (size 3.1-5cm) 94.1%, 57.1%, 37.1%, respectively, and for large tumor (size >5cm) 62.8%, 40.3%, 0%, respectively. Survival of patients treated with PRFA was dependent on tumor size (p<0.001; risk ratio [RR] 9.6, 95% CI 5.2-17.8), number of tumors (p=0.003; RR 1.6, 95% CI 1.2-2.0), combination with PEI (p=0.01; RR 0.6, 95% CI 0.4-0.9), Child-Pugh class (p=0.002; RR 2.0, 95% CI 1.3-3.0) and safety margin (p=0.0026; RR 0.6, 95% CI 0.4-0.9). CONCLUSIONS: PRFA is an effective treatment for HCC. This study showed after PRFA, tumor size, number of tumors, combination with PEI, safety margin, and Child-Pugh class were independent risk factors of survival.     

经皮肝穿刺射频热凝对复发性肝癌的治疗意义

目的 探讨对于无再次手术指征的复发性肝癌行B超引导经皮肝穿刺射频热凝(PRFA)治疗的意义。方法 1999年10月～2001年7月经病理证实为原发性肝癌，术后影像学和血清肿瘤标记物证实为肝癌复发的47患者进行B超引导PRFA治疗。复发瘤灶为单发者24例、多发者23例，其中复发灶为单发且小于3．5cm者12例。定期随访，复查AFP、肝功能和B超，1个月后复查MRI或CT了解肿瘤坏死情况，以后每3个月复查。Kaplan—Meier法计算累积生存率。结果 复发灶为单发者1、2、3年的生存率分别为65.2％、37．5％、37．5％，复发灶为单发且小于3.5cm者1、2、3年的生存率分别为83.3％、51．4％、51．4％。复发灶为多发者1、2年的生存率为41．7％、19．5％。结论 B超引导经皮肝穿刺射频热凝是肝癌综合治疗中一种重要手段，对于无再次手术指征的复发性肝癌可以根据复发瘤灶的大小、范围、复发时间，决定单独或结合TACE给予B超引导经皮肝穿刺射频热凝(PRFA)治疗，可以更加有效地控制复发、提高生存率。     

Quitting Smoking At or Around Diagnosis Improves the Overall Survival of Lung Cancer Patients: A Systematic Review and Meta-Analysis

IntroductionLung cancer (LC) remains a disease with poor prognosis despite recent advances in treatments. Here, we aimed at summarizing the current scientific evidence on whether quitting smoking at or around diagnosis has a beneficial effect on the survival of LC patients.MethodsWe searched MEDLINE and EMBASE for articles published until 31^st October, 2021, that quantified the impact on LC patients’ survival of quitting smoking at or around diagnosis or during treatment. Study-specific data were pooled into summary relative risk (SRR) and corresponding 95% confidence intervals (CI) using random effect meta-analysis models.ResultsTwenty-one articles published between 1980 and 2021 were included, which encompassed a total of over 10,000 LC patients. There was substantial variability across studies in terms of design, patients’ characteristics, treatments received, criteria used to define smoking status (quitters or continued), and duration of follow-up. Quitting smoking at or around diagnosis was significantly associated with improved overall survival (SRR 0.71, 95% CI 0.64–0.80), consistently among patients with non-small cell LC (SRR 0.77, 95% CI 0.66–0.90, n studies = 8), small cell LC (SRR 0.75, 95% CI 0.57–0.99, n studies = 4), or LC of both or unspecified histological type (SRR 0.81, 95% CI 0.68–0.96, n studies = 6).ConclusionsQuitting smoking at or around diagnosis is associated with a beneficial effect on the survival of LC patients. Treating physicians should educate LC patients about the benefits of quitting smoking even after diagnosis and provide them with the necessary smoking cessation support.     

Familiality in breast cancer: a case-control study in a Sweden population.

1330 consecutively diagnosed breast-cancer patients, and an equal number of paired aged-matched controls without breast cancer, were investigated for a familial history of breast cancer. Patients and controls received identical questionnaires. One relative or more with breast cancer was reported by 18.6% of the patients and by 12.3% of the controls, giving a standardized relative risk (SRR) of 1.6 (P < 0.01). One or more first-degree relatives with breast cancer were reported by 11.2% of the patients and by 6.8% of the controls, with an SRR of 1.7 (P < 0.01). For second-degree relatives the SRR was 1.5 (P < 0.05). Of the patients, 3.9% had mothers with breast cancer compared to 2.7% of the controls (SRR = 1.4, N.S.). One or more sisters with breast canceer were reported by 10.1% of the patients and by 5.1% of the controls (SRR = 2.0, P < 0.01). No distinct difference in familiality between the different age groups was found.     

快速康复在不同方式胃癌根治手术中的应用

目的:评价快速康复（fast track,FT）模式在不同方式胃癌根治手术患者术后康复中的有效性及安全性。方法:收集我科2016年1月至2017年6月期间行开放(OS)及腹腔镜(LS)胃癌根治手术患者各40例，随机分为FT处理组（OS+FT组、LS+FT组）和常规处理（NT）对照组（OS+NT组、LS+NT组），比较不同处理模式对术后疼痛评分、恢复情况和术后并发症发生率的影响。结果:OS+FT组、LS+FT组术后1、2、3、4和5 d疼痛评分均低于NT对照组，各观察时点差异均有统计学意义（P＜0.005）；OS+FT组、LS+FT组术后首次排气时间、首次离床时间以及住院时间均短于NT对照组（P＜0.05）；术后OS+FT组、LS+FT组总体并发症发生率均为10%，与NT对照组（OS+NT组20%，LS+NT组15%）相比，差异无统计学意义（P＞0.05）。结论:FT模式有利于减少患者痛苦，加速术后恢复，未增加术后并发症风险，在不同方式胃切除手术患者围术期处理过程中安全、有效。     

A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma

Aims

To assess whether combining percutaneous radiofrequency ablation (PRFA) with transcatheter arterial chemoembolization (TACE) was better than PRFA alone for hepatocellular carcinoma (HCC).

Materials and methods

One hundered twenty patients (with a solitary HCC ≤ 7.0 cm in diameter or multiple HCC (≤3), each ≤3.0 cm in diameter) treated with PRFA combined with TACE were compared with 120 well-matched controls selected from a pool of 652 patients who received PRFA alone during the study period.

Results

The 1-, 2-, 3-, 5-year overall survival rates for the TACE-PRFA and PRFA groups were 93%, 83%, 75%, 50%, and 89%, 76%, 64%, 42%, respectively (p = .045). Subgroup analyses showed the survival for the TACE-PRFA group was better than the PRFA group for tumors >5.0 cm (p = .031) and for multiple tumors (p = .032), but not for tumors ≤5.0 cm (p = .319) and for solitary tumor (p = .128). The 1-, 2-, 3-, 5-year progression free survival (PFS) for the TACE-PRFA and PRFA groups was 90%, 76%, 63%, 42%, and 76%, 60%, 47%, 30%, respectively (p = .002). Child-pugh class, Diameter of tumor and hepatitis B surface antigen (HBsAg) were significant prognostic factors.

Conclusion

Patients treated with TACE-PRFA had better overall survivals than PRFA alone, but only in a subgroup of patients with tumor >5 cm or multiple tumors.